GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (XBUL:SFA) » Definitions » Piotroski F-Score
中文

Sopharma AD-Sofia (XBUL:SFA) Piotroski F-Score

: 4 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sopharma AD-Sofia has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sopharma AD-Sofia's Piotroski F-Score or its related term are showing as below:

XBUL:SFA' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 4

During the past 13 years, the highest Piotroski F-Score of Sopharma AD-Sofia was 6. The lowest was 3. And the median was 5.


Sopharma AD-Sofia Piotroski F-Score Historical Data

The historical data trend for Sopharma AD-Sofia's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma AD-Sofia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 5.00 6.00 6.00 4.00

Sopharma AD-Sofia Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 N/A 4.00 5.00 4.00

Competitive Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia Piotroski F-Score Distribution

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 32.254 + 31.208 + 14.279 + 17.466 = лв95 Mil.
Cash Flow from Operations was 12.709 + -18.096 + -65.241 + 115.661 = лв45 Mil.
Revenue was 467.204 + 449.688 + 458.09 + 499.44 = лв1,874 Mil.
Gross Profit was 103.014 + 103.239 + 86.676 + 111.981 = лв405 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(1255.799 + 1311.711 + 1349.195 + 1439.574 + 1509.892) / 5 = лв1373.2342 Mil.
Total Assets at the begining of this year (Dec22) was лв1,256 Mil.
Long-Term Debt & Capital Lease Obligation was лв127 Mil.
Total Current Assets was лв782 Mil.
Total Current Liabilities was лв608 Mil.
Net Income was 20.681 + 22.684 + 24.519 + 3.237 = лв71 Mil.

Revenue was 397.57 + 405.349 + 415.881 + 444.216 = лв1,663 Mil.
Gross Profit was 82.365 + 88.178 + 90.598 + 98.126 = лв359 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1204.978 + 1198.748 + 1215.889 + 1253.51 + 1255.799) / 5 = лв1225.7848 Mil.
Total Assets at the begining of last year (Dec21) was лв1,205 Mil.
Long-Term Debt & Capital Lease Obligation was лв110 Mil.
Total Current Assets was лв578 Mil.
Total Current Liabilities was лв397 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sopharma AD-Sofia's current Net Income (TTM) was 95. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sopharma AD-Sofia's current Cash Flow from Operations (TTM) was 45. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=95.207/1255.799
=0.07581388

ROA (Last Year)=Net Income/Total Assets (Dec21)
=71.121/1204.978
=0.05902265

Sopharma AD-Sofia's return on assets of this year was 0.07581388. Sopharma AD-Sofia's return on assets of last year was 0.05902265. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sopharma AD-Sofia's current Net Income (TTM) was 95. Sopharma AD-Sofia's current Cash Flow from Operations (TTM) was 45. ==> 45 <= 95 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=126.878/1373.2342
=0.09239356

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=109.74/1225.7848
=0.08952632

Sopharma AD-Sofia's gearing of this year was 0.09239356. Sopharma AD-Sofia's gearing of last year was 0.08952632. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=781.894/607.71
=1.28662355

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=578.377/396.562
=1.45847812

Sopharma AD-Sofia's current ratio of this year was 1.28662355. Sopharma AD-Sofia's current ratio of last year was 1.45847812. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sopharma AD-Sofia's number of shares in issue this year was 172.077. Sopharma AD-Sofia's number of shares in issue last year was 135.986. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=404.91/1874.422
=0.21601859

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=359.267/1663.016
=0.2160334

Sopharma AD-Sofia's gross margin of this year was 0.21601859. Sopharma AD-Sofia's gross margin of last year was 0.2160334. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=1874.422/1255.799
=1.49261307

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=1663.016/1204.978
=1.38012146

Sopharma AD-Sofia's asset turnover of this year was 1.49261307. Sopharma AD-Sofia's asset turnover of last year was 1.38012146. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+0+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sopharma AD-Sofia has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Sopharma AD-Sofia  (XBUL:SFA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sopharma AD-Sofia Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sopharma AD-Sofia (XBUL:SFA) Business Description

Traded in Other Exchanges
Address
5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are organized based on the production of finished products which include Tablet dosage forms, Ampoule dosage forms, Medical products, Other forms, and Other revenue. Geographically company operates in Bulgaria and internationally.

Sopharma AD-Sofia (XBUL:SFA) Headlines

No Headlines